publication date: Sep. 22, 2017
Issue 35 - Sep. 22, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—But at FDA “Maybe” has meaning

    With frustrating photo finish voting results—6-6—still on the screen, FDA’s cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency’s Oncologic Drugs Advisory Committee:

    “Well, that’s the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA’s Oncology Center of Excellence, who gets sarcastic sometimes.

  • Pisters named president of MD Anderson

    Peter Pisters has been named president of MD Anderson Cancer Center and will begin in his new role later this year.

    The University of Texas System Board of Regents approved the appointment Sept. 18. Pisters, currently the president and CEO of University Health Network in Toronto, was unanimously selected as the sole finalist for the position at a board meeting Aug. 25—under state law, university government boards must name finalists for a presidency at least 21 days before making an appointment (The Cancer Letter, Sept. 1).

  • NCI outlines research priorities in annual plan and bypass budget for FY19

    NCI has released its professional judgment budget proposal for the fiscal year 2019, requesting $6.38 billion—$1 billion more than FY17—to fully fund promising areas in cancer research.

  • In Brief

    • NCI awards $12.4 million lymphoma research grant renewal to University of Iowa and Mayo Clinic
    • Roswell Park awarded contract to keep running NY Smokers’ Quitline 
    • ASTRO awards early-career research grants to physician-scientists
  • Drugs and Targets

    • Novartis’s Rydapt gets EU approval for AML and SM indications
    • FDA approves lower dose of cabazitaxel for prostate cancer
    • EMA committee issues positive opinion for Tesaro’s Zejula
    • Opdivo receives Japanese approval for advanced gastric cancer indications

Copyright (c) 2017 The Cancer Letter Inc.